HyperaFRA:HM6A -0.59%68 PEG Ratio is 1.37 as of Jul. 11, 2026, which is 22% below its 10-year median of 1.75. GuruFocus rates FRA:HM6A with a GF Score™ of 68/100 and a GF Value™ of €5.16 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 350 Drug Manufacturers companies, Hypera ranks better than 58.57% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Hypera's PE Ratio without NRI is 8.22. Hypera's 5-Year EBITDA growth rate is 6.00%. Therefore, Hypera's PEG Ratio for today is 1.37.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Hypera's PEG Ratio or its related term are showing as below:
FRA:HM6A'
s PEG Ratio Range Over the Past 10 Years
Min: 0.32 Med: 1.75 Max: 11.95
Current: 1.33
During the past 13 years, Hypera's highest PEG Ratio was 11.95. The lowest was 0.32. And the median was 1.75.
FRA:HM6A's PEG Ratio is ranked better than 58.57% of 350
companies
in the Drug Manufacturers industry
Industry Median: 1.685
vs FRA:HM6A: 1.33
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Hypera (FRA:HM6A) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Hypera PEG Ratio Related Terms
Hypera PEG Ratio Historical Data
* Premium members only.
The historical data trend for Hypera's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hypera's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hypera PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hypera's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Hypera's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Hypera (FRA:HM6A) has a PEG Ratio of 1.37 as of Jul. 11, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Hypera and its competitors. This is 22% below median its historical median of 1.75. Over the past decade, Hypera's PEG Ratio has ranged from 0.32 to 11.95. According to the industry distribution chart, Hypera ranks #145 out of 350 companies in the Drug Manufacturers industry, placing it in the top 41.4%.
Is Hypera's PEG Ratio too high?
Hypera's current PEG Ratio of 1.37 is 22% below median its 10-year median of 1.75. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 11.95. The Drug Manufacturers industry median PEG Ratio is 1.69. Hypera's value of 1.37 is 18.7% below this industry median. Based on the distribution chart, Hypera ranks #145 out of 350 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hypera has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hypera's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hypera ranks #145 out of 350 companies for PEG Ratio. This puts Hypera in the upper half of its industry. The industry median PEG Ratio is 1.69. Hypera's value of 1.37 is 18.7% below this benchmark. Historically, Hypera's own PEG Ratio has ranged from 0.32 to 11.95 over the past decade. While the company's 10-year median is 1.75 vs. the industry median of 1.69, Hypera has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.69, based on 350 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hypera's current PEG Ratio of 1.37 is 18.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Hypera and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hypera's current PEG Ratio is 1.37, which is 22% below median its own 10-year median of 1.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypera stock overvalued right now?
Based on GuruFocus' analysis, Hypera (FRA:HM6A) is currently considered Possible Value Trap. The stock's GF Value™ is €5.16, compared to a current price of €3.38 — trading 34.5% below its estimated fair value. The current PEG Ratio is 1.37, which is 22% below median its 10-year median of 1.75 and 18.7% below the Drug Manufacturers industry median of 1.69. Hypera's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Hypera (FRA:HM6A), the current PEG Ratio is 1.37 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hypera (FRA:HM6A) Overvalued in 2026?
Based on GuruFocus' analysis, Hypera stock appears to be undervalued.
The current stock price of €3.38 is trading 34.5% below its estimated GF Value™ of €5.16.
GuruFocus considers Hypera to be Possible Value Trap.
Key valuation signals for FRA:HM6A:
PEG Ratio: 1.37 (22% below median its 10-year median of 1.75)
GF Value™: €5.16 vs. price of €3.38 (34.5% below fair value)
Industry Position: 18.7% below the Drug Manufacturers median (#145 of 350)
No single metric tells the full story. See the FRA:HM6A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hypera SA is a specialty and generic drug manufacturing company. The company operates in the prescription medicines, over-the-counter (OTC) medicines, branded generics, and generics, and skincare segments within the retail pharmaceutical market. The company also has a wide sales and distribution structure. The company's product portfolio includes key brands in Gastroenterology, Pain, Sun Protection, Skin Moisture, and Cleansing within the over-the-counter (OTC) and Skincare segments, as well as new products in Cardiology, Central Nervous System, and Respiratory System within the prescription medicines segment.
68GF Score
Get the complete analysis for FRA:HM6A
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:HM6A has been successfully added to your 
